This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/522843-eu-drug-regulator-sinovac/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| EU drug regulator launches real-time review of China’s Sinovac coronavirus vaccine | EU drug regulator launches real-time review of China’s Sinovac coronavirus vaccine |
| (4 months later) | |
| The European medicines regulator has started a real-time review of Sinovac’s Covid-19 vaccine, with the drug becoming the first Chinese-developed jab to be evaluated by the bloc. | The European medicines regulator has started a real-time review of Sinovac’s Covid-19 vaccine, with the drug becoming the first Chinese-developed jab to be evaluated by the bloc. |
| The launch of the so-called “rolling review” was announced by the European Medicines Agency (EMA) on Tuesday. | The launch of the so-called “rolling review” was announced by the European Medicines Agency (EMA) on Tuesday. |
| “The… decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies. These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes Covid-19, and may help protect against the disease,” the EMA said in a statement. | “The… decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies. These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes Covid-19, and may help protect against the disease,” the EMA said in a statement. |
| Rolling reviews are aimed at speeding up the approval process of medical drugs. The researchers are allowed to submit their findings for the review in real time rather than waiting for final results and providing the regulator with data in bulk. | Rolling reviews are aimed at speeding up the approval process of medical drugs. The researchers are allowed to submit their findings for the review in real time rather than waiting for final results and providing the regulator with data in bulk. |
| “EMA will assess the compliance of Covid-19 Vaccine (Vero Cell) Inactivated with the usual EU standards for effectiveness, safety and quality,” the regulator added. | “EMA will assess the compliance of Covid-19 Vaccine (Vero Cell) Inactivated with the usual EU standards for effectiveness, safety and quality,” the regulator added. |
| Sinovac’s jab has become the first Chinese-developed coronavirus vaccine to get evaluated by the European drug regulator. Currently, the EMA is also conducting rolling reviews of Russia’s Sputnik V vaccine, as well as jabs by German CureVac and US Novavax pharmaceutical companies. | Sinovac’s jab has become the first Chinese-developed coronavirus vaccine to get evaluated by the European drug regulator. Currently, the EMA is also conducting rolling reviews of Russia’s Sputnik V vaccine, as well as jabs by German CureVac and US Novavax pharmaceutical companies. |
| So far, the Chinese jab has shown rather mixed results with its efficacy ranging from 50% to a solid 90%, according to different studies. The drug has been authorized for use in several countries, including China, Brazil, Turkey, Thailand and Indonesia. | So far, the Chinese jab has shown rather mixed results with its efficacy ranging from 50% to a solid 90%, according to different studies. The drug has been authorized for use in several countries, including China, Brazil, Turkey, Thailand and Indonesia. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |